Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Pfizer's Mixed Outlook: Hold Rating Amidst Vyndaqel's Growth and Falling Demand for Comirnaty and Paxlovid
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Hold Rating on Pfizer: Caution Advised Amid Uncertainties Surrounding Danuglipron
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Pfizer (PFE)
Jefferies Sticks to Their Buy Rating for Pfizer (PFE)
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Pfizer (PFE)
Pfizer Analyst Ratings
Pfizer (PFE) Gets a Buy From Cantor Fitzgerald
Pfizer Analyst Ratings
Pfizer Analyst Ratings
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Wells Fargo Remains a Hold on Pfizer (PFE)
DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating